Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
J Hypertens
; 35 Suppl 1: S57-S63, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-28129247
ABSTRACT
OBJECTIVE:
Recurrent hyperkalemia frequently limits use of renin-angiotensin-aldosterone system inhibitors (RAASi) in chronic kidney disease (CKD) patients with hypertension, diabetes, and/or heart failure. Patiromer is a sodium-free, nonabsorbed potassium (K)-binding polymer approved by the US Food and Drug Administration for the treatment of hyperkalemia. This post-hoc analysis of OPAL-HK examined the effectiveness and safety of patiromer in reducing serum K in hyperkalemic CKD patients on RAASi, with hypertension, receiving diuretic therapy versus those not on diuretics.METHODS:
Depending on the degree of hyperkalemia at baseline, CKD patients with serum K from 5.1 to less than 6.5âmmol/l on RAASi (nâ=â243) were assigned to a patiromer of total dose 8.4 or 16.8âg, divided twice daily. Changes in serum K, and tolerability and safety were assessed over 4 weeks in patients on and not on diuretics.RESULTS:
At baseline, 132 patients used diuretics and 111 were not on diuretics, mean age was 64.3 and 64.0 years, respectively, and 63 and 51% were men. Similar reductions in serum K were seen over 4 weeks in both subgroups. At week 4, serum K fell by -0.95â±â0.04âmmol/l with any diuretic and -1.04â±â0.05âmmol/l with no diuretic. Patiromer was well tolerated, with mild-to-moderate constipation reported as the most common adverse event (7.6 and 14.4% of patients on any diuretic or no diuretic, respectively). Hypokalemia (s-K <3.5âmEq/l) was reported in 2.3% of patients on any diuretic and in 3.7% not on diuretics.CONCLUSION:
The serum K-lowering efficacy and safety profile of patiromer in hyperkalemia patients with CKD was not compromised by diuretic therapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polímeros
/
Quelantes
/
Diuréticos
/
Hiperpotassemia
/
Hipertensão
Tipo de estudo:
Etiology_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article